Targeting Allele-Specific Faulty MRNA In SCNA2 Mutation Patients

A recent Nature study demonstrated allele-specific antisense oligonucleotide (ASO) therapy in two boys with SCN2A mutations causing severe epilepsy and developmental disorders. By targeting only the mutated allele's faulty mRNA — leaving the healthy copy intact — one patient achieved complete seizure elimination and the other saw significant reduction. Both patients also showed improvements in language, motor skills, and behavior. The approach offers a middle ground between symptom management and direct DNA editing, with potential for early intervention in affected infants. CRISPR-based gene correction in mouse models is also being explored as a more permanent solution.

Source: https://hackaday.com/2026/07/23/targeting-allele-specific-faulty-mrna-in-scna2-mutation-patients. 8sync News only summarizes and links out; content copyright belongs to the authors and original sources.